Liquidia Corp
Liquidia is a biopharmaceutical company developing and commercializing treatments for respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It sells YUTREPIA, a dry-powder inhaled treprostinil product, and shares profits from U.S. sales of Sandoz’s generic Treprostinil Injection under a promotion agreement. Liquidia’s commercial field force works with healthcare providers and other stakeholders involved in treating patients and distributing and reimbursing medicines. Liquidia also develops product candidates, including L606, an inhaled, sustained-release treprostinil formulation being studied for PAH and PH-ILD. Its PRINT technology is used to engineer drug particles, including those in YUTREPIA. Liquidia manufactures engineered drug particles at its 45,000 square foot facility in Morrisville, North Carolina, and uses contract manufacturers for other production and supply activities.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Analysts from Wells Fargo and Bank of America Securities provided ratings and price targets for Xenon (XENE), Veeva Systems (VEEV), and Liquidia Technologies (LQDA). Xenon received a Buy rating with a $64 target, Veeva a Buy with a $400 target, and Liquidia a Hold with a $54 target. Consensus ratings and targets also provided.
JPMorgan upgraded Mercury Systems (MRCY) to Overweight with a $102 target, citing Q3 performance. Republic Services (RSG) was upgraded to Overweight with a $295 target, expecting positive waste volume growth in 2027. Raymond James upgraded Liquidia (LQDA) to Strong Buy with a $77 target, citing strong demand and legal settlement. Piper Sandler upgraded Alpha Tau (DRTS) to Overweight with a $22 target, highlighting its technology.
Raymond James upgraded Liquidia Technologies (LQDA) to Strong Buy, raising its price target to $77 from $53. The company's Yutrepia product showed strong sales, with $227.7M in Q3 2026 product sales and a 92.5% gross profit margin. LQDA reported Q3 revenue of $225.3M, beating estimates, driven by Yutrepia's 31% quarterly sales growth. Analysts have mixed but generally positive outlooks on LQDA's future performance.
Over the past 7 days, AlphAI's AI scored 29 news stories mentioning LQDA (Liquidia Corp). Coverage has skewed bullish: 13 bullish, 5 neutral, and 11 bearish.
Recent LQDA coverage spans earnings and financial news.
In the last 30 days, LQDA insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($98K). The most active reporter was Adair Jason, Chief Business Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Hold rating tempers upside expectations.
Upgrade could spark buying.
Upgrade and higher target suggest upside potential.
Analyst target raise suggests potential upside for the stock.
Analyst upgrades and earnings beat suggest upside potential.
AlphAI scores every news story that mentions LQDA with an AI model for sentiment and relevance, and aggregates insider trades from Liquidia Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts from Wells Fargo and Bank of America Securities provided ratings and price targets for Xenon (XENE), Veeva Systems (VEEV), and Liquidia Technologies (LQDA). Xenon received a Buy rating with a $64 target, Veeva a Buy with a $400 target, and Liquidia a Hold with a $54 target. Consensus ratings and targets also provided.
JPMorgan upgraded Mercury Systems (MRCY) to Overweight with a $102 target, citing Q3 performance. Republic Services (RSG) was upgraded to Overweight with a $295 target, expecting positive waste volume growth in 2027. Raymond James upgraded Liquidia (LQDA) to Strong Buy with a $77 target, citing strong demand and legal settlement. Piper Sandler upgraded Alpha Tau (DRTS) to Overweight with a $22 target, highlighting its technology.
Raymond James upgraded Liquidia Technologies (LQDA) to Strong Buy, raising its price target to $77 from $53. The company's Yutrepia product showed strong sales, with $227.7M in Q3 2026 product sales and a 92.5% gross profit margin. LQDA reported Q3 revenue of $225.3M, beating estimates, driven by Yutrepia's 31% quarterly sales growth. Analysts have mixed but generally positive outlooks on LQDA's future performance.
BofA Securities raised its price target for Liquidia Technologies (LQDA) to $54 from $42, citing strong momentum in Yutrepia PAH sales. The company reported Q3 revenue of $225.3M, beating estimates, and Yutrepia sales of $222.7M. Multiple analysts increased their price targets, with varying ratings.
Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.
Needham reaffirmed its Buy rating for Liquidia and increased its price target to $66 from $58, suggesting a 28.4% upside from the Nov 10 close of $51.40. Recent analyst price targets for Liquidia range from $33 to $87.
BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.
Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.
Liquidia Corporation (LQDA) reported a Q3 loss of $2.64 per share, missing estimates, but revenue of $225.3M beat expectations. The loss included a $389.7M litigation settlement. YUTREPIA sales rose 331% YoY. Shares dipped 0.77% premarket. Cash reserves were $396.1M as of Q3. R&D and SG&A expenses increased significantly.
Liquidia Corp. (LQDA) may see a 6.5% stock move on its Nov. 10 earnings release, according to options data. Past earnings moves have varied significantly from implied ranges, with both larger and smaller actual moves observed. The company reports before market open.
